VRTX
Vertex Pharmaceuticals Incorporated
Price Chart
Latest Quote
$446.83
+5.09 (+1.15%)
Current Price
| Previous Close | $441.74 |
| Open | $446.03 |
| Day High | $453.16 |
| Day Low | $443.86 |
| Volume | 1,528,438 |
Stock Information
| Shares Outstanding | 253.81M |
| Total Debt | $1.99B |
| Cash Equivalents | $7.25B |
| Revenue | $12.22B |
| Net Income | $4.34B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $113.41B |
| P/E Ratio | 26.55 |
| EPS (TTM) | $16.83 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $106.86B |
| Sales | $12.22B |
| Income | $4.34B |
| Book/sh | $76.18 |
| Cash/sh | $28.55 |
| Employees | 6K |
Financial Ratios
| Quick Ratio | 2.38 |
| Current Ratio | 3.02 |
| Debt/Eq | 10.26 |
| EPS Growth TTM | 59.60% |
Returns & Margins
| ROA | 12.14% |
| ROE | 24.20% |
| Gross Margin | 54.39% |
| Operating Margin | 38.13% |
| Profit Margin | 35.51% |
Ownership
| Insider Ownership | 0.20% |
| Institutional Ownership | 97.89% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 20.81 |
| PEG | 1.60 |
| P/S | 9.28 |
| P/B | 5.87 |
Analyst Data
| Recommendation | buy |
| Target Price | $548.69 |
Technical Indicators
| SMA20 | $438.61 |
| SMA50 | $436.94 |
| SMA200 | $437.17 |
| RSI | 57.19 |
| ATR | 11.2214 |
| Shares Float | 253.02M |
| Short Float | 1.99% |
| Short Ratio | 3.97 |
| Volatility | 0.31 |
| Rel Volume | 1.14 |
Performance History
| Week | -0.16% |
| Month | +4.48% |
| Quarter | -2.16% |
| 6 Months | -3.52% |
| YTD | -1.17% |
| Year | +0.22% |
| 3 Years | +38.09% |
| 5 Years | +114.17% |
| 10 Years | +365.01% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $446.83 | 1,528,438 |
| 2026-06-04 | $441.74 | 1,362,300 |
| 2026-06-03 | $428.34 | 1,564,400 |
| 2026-06-02 | $425.09 | 1,147,100 |
| 2026-06-01 | $438.40 | 1,115,200 |
| 2026-05-29 | $447.54 | 1,893,400 |
| 2026-05-28 | $447.97 | 1,357,900 |
| 2026-05-27 | $437.22 | 1,164,400 |
| 2026-05-26 | $435.93 | 865,800 |
| 2026-05-22 | $434.52 | 1,746,300 |
| 2026-05-21 | $433.54 | 1,395,200 |
| 2026-05-20 | $430.44 | 1,784,800 |
| 2026-05-19 | $434.31 | 1,219,500 |
| 2026-05-18 | $436.58 | 1,451,000 |
| 2026-05-15 | $436.95 | 1,288,900 |
| 2026-05-14 | $450.41 | 1,088,200 |
| 2026-05-13 | $453.06 | 1,194,200 |
| 2026-05-12 | $448.29 | 1,398,000 |
| 2026-05-11 | $435.17 | 1,264,200 |
| 2026-05-08 | $429.82 | 953,300 |
| 2026-05-07 | $425.00 | 1,112,300 |
| 2026-05-06 | $427.65 | 1,203,200 |
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
đ° Latest News
Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?
Zacks âĸ 2026-06-05T15:30:18Z
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?
Zacks âĸ 2026-06-04T15:30:18Z
The Best Stocks to Invest $500 in Right Now
Motley Fool âĸ 2026-06-04T07:05:00Z
Vertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-03T15:30:13Z
Is Vertex Pharmaceuticals (VRTX) Offering An Opportunity After Recent Share Price Consolidation?
Simply Wall St. âĸ 2026-06-02T21:16:46Z
Should FDAâs IgA Nephropathy BLA Acceptance for Povetacicept Reshape Vertex Pharmaceuticalsâ (VRTX) Investment Narrative?
Simply Wall St. âĸ 2026-06-02T16:09:45Z
Got $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely Mispricing
24/7 Wall St. âĸ 2026-06-02T16:02:49Z
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
Zacks âĸ 2026-06-02T15:09:00Z
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?
Barchart âĸ 2026-06-01T18:03:37Z
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?
Zacks âĸ 2026-06-01T13:24:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,651,300,000 | $1,530,500,000 | $1,262,200,000 | $1,080,300,000 |
| Cost Of Revenue | $1,651,300,000 | $1,530,500,000 | $1,262,200,000 | $1,080,300,000 |
| Total Revenue | $12,001,300,000 | $11,020,100,000 | $9,869,200,000 | $8,930,700,000 |
| Operating Revenue | $11,970,600,000 | $11,020,100,000 | $9,869,200,000 | $8,930,700,000 |
| Expenses | ||||
| Interest Expense | $13,300,000 | $30,600,000 | $44,100,000 | $54,800,000 |
| Total Expenses | $7,446,900,000 | $11,253,500,000 | $6,088,800,000 | $4,680,800,000 |
| Other Income Expense | $-388,800,000 | $-85,600,000 | $28,800,000 | $-107,300,000 |
| Other Non Operating Income Expenses | $-7,700,000 | $-86,100,000 | $-22,800,000 | $-164,800,000 |
| Net Non Operating Interest Income Expense | $477,600,000 | $567,500,000 | $570,600,000 | $89,800,000 |
| Interest Expense Non Operating | $13,300,000 | $30,600,000 | $44,100,000 | $54,800,000 |
| Operating Expense | $5,795,600,000 | $9,723,000,000 | $4,826,600,000 | $3,600,500,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Interest Income | $477,600,000 | $567,500,000 | $570,600,000 | $89,800,000 |
| Interest Income | $490,900,000 | $598,100,000 | $614,700,000 | $144,600,000 |
| Normalized Income | $4,277,666,859 | $-535,995,000 | $3,576,978,400 | $3,276,862,500 |
| Net Income From Continuing And Discontinued Operation | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Total Operating Income As Reported | $4,173,300,000 | $-232,900,000 | $3,832,000,000 | $4,307,400,000 |
| Net Income Common Stockholders | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Income | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Income Including Noncontrolling Interests | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Income Continuous Operations | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Pretax Income | $4,643,200,000 | $248,500,000 | $4,379,800,000 | $4,232,400,000 |
| Special Income Charges | $-381,100,000 | $500,000 | $51,600,000 | $57,500,000 |
| Interest Income Non Operating | $490,900,000 | $598,100,000 | $614,700,000 | $144,600,000 |
| Operating Income | $4,554,400,000 | $-233,400,000 | $3,780,400,000 | $4,249,900,000 |
| Gross Profit | $10,350,000,000 | $9,489,600,000 | $8,607,000,000 | $7,850,400,000 |
| Per Share | ||||
| Diluted EPS | $15.32 | $-2.08 | $13.89 | $12.82 |
| Basic EPS | $15.46 | $-2.08 | $14.05 | $12.97 |
| Other | ||||
| Tax Effect Of Unusual Items | $-56,633,141 | $105,000 | $8,978,400 | $12,362,500 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $5,247,400,000 | $485,800,000 | $4,553,600,000 | $4,378,000,000 |
| Total Unusual Items | $-381,100,000 | $500,000 | $51,600,000 | $57,500,000 |
| Total Unusual Items Excluding Goodwill | $-381,100,000 | $500,000 | $51,600,000 | $57,500,000 |
| Reconciled Depreciation | $209,800,000 | $207,200,000 | $181,300,000 | $148,300,000 |
| EBITDA (Bullshit earnings) | $4,866,300,000 | $486,300,000 | $4,605,200,000 | $4,435,500,000 |
| EBIT | $4,656,500,000 | $279,100,000 | $4,423,900,000 | $4,287,200,000 |
| Diluted Average Shares | $258,000,000 | $257,900,000 | $260,500,000 | $259,100,000 |
| Basic Average Shares | $255,700,000 | $257,900,000 | $257,700,000 | $256,100,000 |
| Diluted NI Availto Com Stockholders | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Tax Provision | $690,000,000 | $784,100,000 | $760,200,000 | $910,400,000 |
| Impairment Of Capital Assets | $379,000,000 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $2,100,000 | $-500,000 | $-51,600,000 | $-57,500,000 |
| Research And Development | $4,042,500,000 | $8,258,700,000 | $3,690,000,000 | $2,655,800,000 |
| Selling General And Administration | $1,753,100,000 | $1,464,300,000 | $1,136,600,000 | $944,700,000 |
| Other Special Charges | - | $4,628,400,000 | $527,100,000 | $115,500,000 |
Fetched: 2026-05-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $17,153,600,000 | $14,495,700,000 | $15,652,500,000 | $12,221,100,000 |
| Total Assets | $25,643,000,000 | $22,533,200,000 | $22,730,200,000 | $18,150,900,000 |
| Total Non Current Assets | $14,442,000,000 | $12,936,800,000 | $8,586,000,000 | $4,916,100,000 |
| Other Non Current Assets | $1,236,600,000 | $999,300,000 | $895,300,000 | $409,600,000 |
| Non Current Deferred Assets | $2,897,900,000 | $2,331,100,000 | $1,812,100,000 | $1,246,900,000 |
| Non Current Deferred Taxes Assets | $2,897,900,000 | $2,331,100,000 | $1,812,100,000 | $1,246,900,000 |
| Investmentin Financial Assets | $5,712,300,000 | $5,107,900,000 | $2,497,800,000 | $112,200,000 |
| Goodwill And Other Intangible Assets | $1,512,200,000 | $1,913,900,000 | $1,927,900,000 | $1,691,600,000 |
| Other Intangible Assets | $424,200,000 | $825,900,000 | $839,900,000 | $603,600,000 |
| Current Assets | $11,201,000,000 | $9,596,400,000 | $14,144,200,000 | $13,234,800,000 |
| Other Current Assets | $110,900,000 | $76,400,000 | $84,300,000 | $74,400,000 |
| Hedging Assets Current | $6,200,000 | $130,100,000 | $1,800,000 | $47,500,000 |
| Prepaid Assets | $736,200,000 | $459,200,000 | $537,600,000 | $431,600,000 |
| Inventory | $1,686,800,000 | $1,205,400,000 | $738,800,000 | $460,600,000 |
| Receivables | $2,052,800,000 | $1,609,400,000 | $1,563,400,000 | $1,442,200,000 |
| Accounts Receivable | $2,052,800,000 | $1,609,400,000 | $1,563,400,000 | $1,442,200,000 |
| Cash Cash Equivalents And Short Term Investments | $6,608,100,000 | $6,115,900,000 | $11,218,300,000 | $10,778,500,000 |
| Cash And Cash Equivalents | $5,084,800,000 | $4,569,600,000 | $10,369,100,000 | $10,504,000,000 |
| Debt | ||||
| Total Debt | $2,030,500,000 | $1,744,300,000 | $808,400,000 | $899,700,000 |
| Long Term Debt And Capital Lease Obligation | $1,953,200,000 | $1,657,200,000 | $724,700,000 | $810,300,000 |
| Current Debt And Capital Lease Obligation | $77,300,000 | $87,100,000 | $83,700,000 | $89,400,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,977,200,000 | $6,123,600,000 | $5,149,800,000 | $4,238,200,000 |
| Total Non Current Liabilities Net Minority Interest | $3,116,000,000 | $2,559,000,000 | $1,602,400,000 | $1,496,100,000 |
| Other Non Current Liabilities | $267,400,000 | $203,200,000 | $196,300,000 | $233,000,000 |
| Tradeand Other Payables Non Current | $895,400,000 | $698,600,000 | $681,400,000 | $452,800,000 |
| Current Liabilities | $3,861,200,000 | $3,564,600,000 | $3,547,400,000 | $2,742,100,000 |
| Other Current Liabilities | $127,700,000 | $36,600,000 | $50,700,000 | $62,500,000 |
| Current Deferred Liabilities | $171,800,000 | $206,800,000 | $170,300,000 | $159,600,000 |
| Payables And Accrued Expenses | $3,484,400,000 | $3,234,100,000 | $3,242,700,000 | $2,430,600,000 |
| Payables | $893,000,000 | $877,600,000 | $924,500,000 | $642,200,000 |
| Other Payable | $328,200,000 | $303,500,000 | $460,100,000 | $215,000,000 |
| Total Tax Payable | $103,100,000 | $161,100,000 | $99,500,000 | $123,300,000 |
| Accounts Payable | $461,700,000 | $413,000,000 | $364,900,000 | $303,900,000 |
| Equity | ||||
| Common Stock Equity | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Total Equity Gross Minority Interest | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Stockholders Equity | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Gains Losses Not Affecting Retained Earnings | $-15,900,000 | $127,800,000 | $-14,300,000 | $800,000 |
| Other Equity Adjustments | $-15,900,000 | $127,800,000 | $-14,300,000 | $800,000 |
| Retained Earnings | $13,560,000,000 | $9,606,800,000 | $10,142,400,000 | $6,522,800,000 |
| Other | ||||
| Ordinary Shares Number | $253,991,224 | $256,940,382 | $257,695,221 | $257,011,628 |
| Share Issued | $253,991,224 | $256,940,382 | $257,695,221 | $257,011,628 |
| Tangible Book Value | $17,153,600,000 | $14,495,700,000 | $15,652,500,000 | $12,221,100,000 |
| Invested Capital | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Working Capital | $7,339,800,000 | $6,031,800,000 | $10,596,800,000 | $10,492,700,000 |
| Capital Lease Obligations | $2,030,500,000 | $1,744,300,000 | $808,400,000 | $899,700,000 |
| Total Capitalization | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Additional Paid In Capital | $5,119,200,000 | $6,672,400,000 | $7,449,700,000 | $7,386,500,000 |
| Capital Stock | $2,500,000 | $2,600,000 | $2,600,000 | $2,600,000 |
| Common Stock | $2,500,000 | $2,600,000 | $2,600,000 | $2,600,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,953,200,000 | $1,657,200,000 | $724,700,000 | $810,300,000 |
| Current Deferred Revenue | $171,800,000 | $206,800,000 | $170,300,000 | $159,600,000 |
| Current Capital Lease Obligation | $77,300,000 | $87,100,000 | $83,700,000 | $89,400,000 |
| Current Accrued Expenses | $2,591,400,000 | $2,356,500,000 | $2,318,200,000 | $1,788,400,000 |
| Investments And Advances | $5,712,300,000 | $5,107,900,000 | $2,497,800,000 | $112,200,000 |
| Available For Sale Securities | $5,712,300,000 | $5,107,900,000 | $2,497,800,000 | $112,200,000 |
| Goodwill | $1,088,000,000 | $1,088,000,000 | $1,088,000,000 | $1,088,000,000 |
| Net PPE | $3,083,000,000 | $2,584,600,000 | $1,452,900,000 | $1,455,800,000 |
| Accumulated Depreciation | $-1,204,100,000 | $-1,064,800,000 | $-1,188,900,000 | $-1,027,300,000 |
| Gross PPE | $4,287,100,000 | $3,649,400,000 | $2,641,800,000 | $2,483,100,000 |
| Leases | $1,009,300,000 | $737,600,000 | $474,600,000 | $410,900,000 |
| Other Properties | $1,562,700,000 | $1,356,800,000 | $293,600,000 | $347,400,000 |
| Machinery Furniture Equipment | $1,198,200,000 | $1,060,700,000 | $911,900,000 | $788,600,000 |
| Buildings And Improvements | $483,800,000 | $461,200,000 | $928,600,000 | $903,100,000 |
| Land And Improvements | $33,100,000 | $33,100,000 | $33,100,000 | $33,100,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $230,100,000 | $184,600,000 | $135,000,000 | $161,800,000 |
| Work In Process | $1,196,900,000 | $768,800,000 | $525,100,000 | $260,700,000 |
| Raw Materials | $259,800,000 | $252,000,000 | $78,700,000 | $38,100,000 |
| Other Short Term Investments | $1,523,300,000 | $1,546,300,000 | $849,200,000 | $274,500,000 |
| Treasury Shares Number | - | - | $0 | $0 |
Fetched: 2026-05-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $3,193,800,000 | $-978,000,000 | $3,278,900,000 | $3,925,200,000 |
| Operating Activities | ||||
| Operating Cash Flow | $3,631,400,000 | $-492,600,000 | $3,537,300,000 | $4,129,900,000 |
| Cash Flow From Continuing Operating Activities | $3,631,400,000 | $-492,600,000 | $3,537,300,000 | $4,129,900,000 |
| Operating Gains Losses | - | $57,700,000 | $600,000 | $149,100,000 |
| Investing Activities | ||||
| Capital Expenditure | $-437,600,000 | $-485,400,000 | $-258,400,000 | $-204,700,000 |
| Investing Cash Flow | $-945,400,000 | $-3,770,000,000 | $-3,141,700,000 | $-321,100,000 |
| Cash Flow From Continuing Investing Activities | $-945,400,000 | $-3,770,000,000 | $-3,141,700,000 | $-321,100,000 |
| Net Other Investing Changes | $-24,700,000 | $-54,000,000 | $-31,000,000 | $-47,800,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-2,387,300,000 | $-1,582,100,000 | $-653,700,000 | $-172,000,000 |
| Financing Cash Flow | $-2,261,300,000 | $-1,494,900,000 | $-562,200,000 | $-67,700,000 |
| Cash Flow From Continuing Financing Activities | $-2,261,300,000 | $-1,494,900,000 | $-562,200,000 | $-67,700,000 |
| Net Other Financing Charges | $3,700,000 | $6,200,000 | $1,800,000 | $3,500,000 |
| Net Common Stock Issuance | $-2,387,300,000 | $-1,582,100,000 | $-653,700,000 | $-172,000,000 |
| Other | ||||
| Repayment Of Debt | $-5,400,000 | $-33,600,000 | $-44,900,000 | $-85,500,000 |
| Interest Paid Supplemental Data | $12,400,000 | $30,500,000 | $43,100,000 | $52,300,000 |
| Income Tax Paid Supplemental Data | $1,566,700,000 | $1,082,100,000 | $1,677,300,000 | $1,057,800,000 |
| End Cash Position | $5,087,800,000 | $4,572,200,000 | $10,372,300,000 | $10,512,000,000 |
| Beginning Cash Position | $4,572,200,000 | $10,372,300,000 | $10,512,000,000 | $6,800,100,000 |
| Effect Of Exchange Rate Changes | $90,900,000 | $-42,600,000 | $26,900,000 | $-29,200,000 |
| Changes In Cash | $424,700,000 | $-5,757,500,000 | $-166,600,000 | $3,741,100,000 |
| Proceeds From Stock Option Exercised | $127,700,000 | $114,600,000 | $134,600,000 | $186,300,000 |
| Common Stock Payments | $-2,387,300,000 | $-1,582,100,000 | $-653,700,000 | $-172,000,000 |
| Net Issuance Payments Of Debt | $-5,400,000 | $-33,600,000 | $-44,900,000 | $-85,500,000 |
| Net Long Term Debt Issuance | $-5,400,000 | $-33,600,000 | $-44,900,000 | $-85,500,000 |
| Long Term Debt Payments | $-5,400,000 | $-33,600,000 | $-44,900,000 | $-85,500,000 |
| Net Investment Purchase And Sale | $-483,100,000 | $-3,230,600,000 | $-2,852,300,000 | $227,300,000 |
| Sale Of Investment | $5,913,400,000 | $4,465,600,000 | $934,200,000 | $920,000,000 |
| Purchase Of Investment | $-6,396,500,000 | $-7,696,200,000 | $-3,786,500,000 | $-692,700,000 |
| Net Intangibles Purchase And Sale | $0 | $-187,700,000 | $-58,000,000 | $0 |
| Purchase Of Intangibles | $0 | $-187,700,000 | $-58,000,000 | $0 |
| Net PPE Purchase And Sale | $-437,600,000 | $-297,700,000 | $-200,400,000 | $-204,700,000 |
| Purchase Of PPE | $-437,600,000 | $-297,700,000 | $-200,400,000 | $-204,700,000 |
| Change In Working Capital | $-1,199,100,000 | $-514,800,000 | $-265,700,000 | $340,800,000 |
| Change In Other Current Liabilities | $148,500,000 | $39,700,000 | $208,900,000 | $498,900,000 |
| Change In Payables And Accrued Expense | $-80,100,000 | $262,400,000 | $478,100,000 | $663,300,000 |
| Change In Accrued Expense | $-116,900,000 | $212,900,000 | $429,400,000 | $542,500,000 |
| Change In Payable | $36,800,000 | $49,500,000 | $48,700,000 | $120,800,000 |
| Change In Account Payable | $36,800,000 | $49,500,000 | $48,700,000 | $120,800,000 |
| Change In Prepaid Assets | $-396,000,000 | $-200,300,000 | $-545,700,000 | $-326,400,000 |
| Change In Inventory | $-524,200,000 | $-517,300,000 | $-322,900,000 | $-136,400,000 |
| Change In Receivables | $-347,300,000 | $-99,300,000 | $-84,100,000 | $-358,600,000 |
| Changes In Account Receivables | $-347,300,000 | $-99,300,000 | $-84,100,000 | $-358,600,000 |
| Other Non Cash Items | $113,400,000 | $900,000 | $-42,600,000 | $-45,700,000 |
| Stock Based Compensation | $685,900,000 | $698,500,000 | $581,200,000 | $491,300,000 |
| Asset Impairment Charge | $379,000,000 | $0 | $0 | - |
| Deferred Tax | $-510,800,000 | $-348,800,000 | $-536,500,000 | $-275,900,000 |
| Deferred Income Tax | $-510,800,000 | $-348,800,000 | $-536,500,000 | $-275,900,000 |
| Depreciation Amortization Depletion | $209,800,000 | $207,200,000 | $181,300,000 | $148,300,000 |
| Depreciation And Amortization | $209,800,000 | $207,200,000 | $181,300,000 | $148,300,000 |
| Net Income From Continuing Operations | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-295,900,000 |
| Purchase Of Business | - | $0 | $0 | $-295,900,000 |
| Gain Loss On Investment Securities | - | $57,700,000 | $600,000 | $149,100,000 |
| Issuance Of Debt | - | - | $1,800,000 | $0 |
| Long Term Debt Issuance | - | - | $1,800,000 | $0 |
| Depreciation | - | - | - | $148,300,000 |
Fetched: 2026-05-26